RxDoctor Payments Data

Michael Bohlman, MD

Family Medicine · Madera, CANPI 1386756799

Payments from drug & device makers

$1,227in general payments, 2019–2025

Across 73 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$174
  • Alnylam Pharmaceuticals Inc.$154
  • Boehringer Ingelheim$152
  • AstraZeneca$90
  • Novo Nordisk$84
  • Johnson & Johnson$82
  • plus $492 from 16 others

What the payments were for

  • Food & beverage$1,21399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,227 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$31,974
Medicare patients
70
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$100,943
JardianceEmpagliflozin108$96,727
OzempicSemaglutide28$67,850
Dupixent SyringeDupilumab14$54,842
XareltoRivaroxaban60$39,644
TrulicityDulaglutide25$36,353
Spiriva RespimatTiotropium Bromide39$26,900
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$21,354
Breo ElliptaFluticasone/Vilanterol35$14,865
JanuviaSitagliptin Phosphate19$14,745
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$12,901
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,181
ArexvyRsvpref3 Antigen/As01e/Pf31$8,895
Tresiba Flextouch U-100Insulin Degludec20$8,444
SymbicortBudesonide/Formoterol Fumarate23$8,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$152$144,981174 claims
Novo NordiskOzempic$84$67,85028 claims
GSKBreo Ellipta, Trelegy Ellipta, Arexvy, Shingrix$78$41,140115 claims
Johnson & JohnsonXarelto$82$39,64460 claims
Lilly USA, LLCTrulicity$41$36,35325 claims
AstraZenecaSymbicort, Brilinta$90$15,43137 claims
AbbVieLumigan$27$4,40917 claims
Sanofi-aventis U.S. LLCLantus$29$2,28227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Madera

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →